## State of Oklahoma Oklahoma Health Care Authority Besponsa® (Inotuzumab Ozogamicin) Prior Authorization



Member Name:	Date of Birth:	Member ID#:
Drug Information		
☐ Physician billing (HCPCS code:		e (or date of next dose):
Billing Provider Information		
SoonerCare Provider ID:	Provider Name:	
Provider Phone:	Provider F	ēax:
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	_ Prescriber Fax:	Specialty:
Criteria		
<ol> <li>Will inotuzumab ozogamicin be used as a single-agent? Yes No</li> <li>Please indicate the diagnosis and information:         <ul> <li>Acute Lymphoblastic Leukemia (ALL)</li> <li>A. What is the Philadelphia chromosome status of the leukemia?</li> <li>Philadelphia chromosome negative (Ph-) ALL</li> <li>Philadelphia chromosome positive (Ph+) ALL</li> <li>Unknown</li> <li>B. Does the patient have relapsed or refractory disease? Yes No</li> <li>C. Is member intolerant/refractory to two or more Tyrosine Kinase Inhibitors (TKIs)? Yes No</li> <li>If answer is none of the above, please indicate diagnosis:</li> </ul> </li> <li>Additional Information:</li> </ol>		
For Continued Authorization:  1. Date of last dose:  2. Does member have any evidence of progressive disease while on inotuzumab ozogamicin?  YesNo  3. Has the member experienced adverse drug reactions related to inotuzumab ozogamicin therapy?  YesNo  If yes, please specify adverse reactions:  Additional Information:  Prescriber Signature:  L certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.		

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

will result in processing delays.

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.